HFS
RIGL icon

Hantz Financial Services’s Rigel Pharmaceuticals RIGL Stock Holding History

Hantz Financial Services’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed – – 1212
2023
Q3 		$0 Hold
3
– – ﹤0.01% 1182
2023
Q2 		$0 Hold
3
– – ﹤0.01% 1161
2023
Q1 		$0 Buy
+3
New +$48 ﹤0.01% 1187

Other funds holding RIGL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Hantz Financial Services's RIGL Position: Q4 2023 in Review

Hantz Financial Services sold out of Rigel Pharmaceuticals (RIGL) in Q4 2023, closing a stake of 3 shares.

Hantz Financial Services first reported a position in RIGL in Q1 2023 and held it in 3 quarters. The position peaked at $0 in Q3 2023. 112 funds tracked by Wall St. Rank hold RIGL as of Q4 2023.

  • Hantz Financial Services reported no remaining Rigel Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Hantz Financial Services sold 3 Rigel Pharmaceuticals shares in Q4 2023.
  • Hantz Financial Services first reported a position in Rigel Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Hantz Financial Services's Rigel Pharmaceuticals position peaked at $0 in Q3 2023.
  • 112 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2023.

Based on Hantz Financial Services's 13F filing for Q4 2023, filed 14 Feb 2024.